Jun 2026 (Q2 FY26) — Aug 11, 2026
LENZ Therapeutics Q2 FY26 — Strong July Script Growth and Promising Patient Persistence
Read the full callLENZ Therapeutics (LENZ) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
LENZ Therapeutics earnings: last reported Tue, 11 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 5.5 | +9.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -622.9 | −285.8 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -31.9 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$3.3 +0.92% · +$0.03
Performance −91.4% 1Y
1Y: $38.26 on 17 Oct 2025 → $3.3. High $38.26 (17 Oct 2025), low $3.27 (16 Oct 2026).
- Previous close
- $3.27
- 52-week range
- $3.27 – $36.31
- One year
- −90.91%
Overview
- Symbol
- LENZ
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
LENZ Therapeutics earnings calls (LENZ)
Financials
What the filings say
Net profit, year on year: −114% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 5 | 13 | 2 | 2 | 5 |
| Expenses | — | — | 17 | 22 | — | — | 46 | 40 |
| Operating profit | -13 | -15 | -17 | -17 | -19 | -38 | -44 | -34 |
| Operating margin | — | — | — | −337.1% | −151.1% | −2422.1% | −2321.7% | −622.9% |
| Other income | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 |
| Profit before tax | -10 | — | — | -14 | -17 | -36 | — | -32 |
| Tax rate | 0.0% | — | — | −3.5% | 0.0% | −0.0% | — | −0.0% |
| Net profit | -10 | -13 | -15 | -15 | -17 | -36 | -41 | -32 |
| EPS ($ per share) | -0.38 | — | -0.53 | -0.53 | -0.59 | — | -1.32 | -1.02 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Equity capital | — | 0 | 0 | 0 | 0 | 0 |
| Reserves | -71 | -141 | -242 | -95 | -145 | -227 |
| Total liabilities | 32 | 18 | 26 | 20 | 11 | 22 |
| Fixed assets | 1 | 7 | 23 | 0 | 1 | 1 |
| Total assets | 23 | 402 | 322 | 70 | 215 | 306 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Cash from operations | -9 | -53 | -88 | -60 | -59 | -69 |
| Cash from investing | -2 | -6 | -242 | -30 | -154 | -76 |
| Cash from financing | 30 | 417 | 1 | 81 | 199 | 150 |
| Net cash flow | 20 | 359 | -329 | -9 | -15 | 5 |
| Capital expenditure | -2 | -6 | -7 | -0 | -0 | -1 |
| Free cash flow | -10 | -59 | -95 | -60 | -60 | -70 |
Insider filings
9 filings between Nov 7, 2025 and Mar 27, 2026.
Open market
decisions to buy or sellPurchases
$654.9K
6 purchases by 4 insiders
Sales
$261.0K
2 sales by 1 insider
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 1
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Olsson Shawn | — | $261.0K | Nov 17, 2025 |
| Schimmelpennink Evert B. | $251.4K | — | Mar 27, 2026 |
| MCCOLLUM JAMES W | $239.3K | — | Nov 7, 2025 |
| Chevallard Daniel R. | $114.3K | — | Mar 27, 2026 |
| George Jeffrey P. | $49.9K | — | Mar 27, 2026 |
Latest filings (46)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Mar 27, 2026 | Schimmelpennink Evert B. President, CEO and Secretary | Purchase | 28,089 | $251.4K |
| Mar 27, 2026 | George Jeffrey P. Director | Purchase | 5,592 | $49.9K |
| Mar 27, 2026 | Chevallard Daniel R. Chief Financial Officer | Purchase | 7,500 | $64.3K |
| Nov 17, 2025 | Olsson Shawn Chief Commercial Officer | Sale 10b5-1 plan | 4,212 | $108.4K |
| Nov 17, 2025 | Olsson Shawn Chief Commercial Officer | Option exercise 10b5-1 plan | 10,000 | $20.8K |
| Nov 17, 2025 | Olsson Shawn Chief Commercial Officer | Sale 10b5-1 plan | 5,788 | $152.6K |
| Nov 7, 2025 | MCCOLLUM JAMES W Director | Purchase | 10,500 | $239.3K |
| Nov 7, 2025 | Chevallard Daniel R. Chief Financial Officer | Purchase | 2,178 | $49.6K |
| Nov 7, 2025 | Chevallard Daniel R. Chief Financial Officer | Purchase | 20 | $454 |
| Sep 30, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 57,502 | $2.67M |
| Sep 30, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 49,701 | $2.25M |
| Sep 30, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 34,405 | $1.56M |
| Sep 30, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 83,066 | $3.85M |
| Sep 30, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 177 | $8.3K |
| Sep 30, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 123 | $5.8K |
| Sep 18, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 49,479 | $2.06M |
| Sep 18, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 24,370 | $1.01M |
| Sep 18, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 40,907 | $1.76M |
| Sep 18, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 20,148 | $866.4K |
| Sep 18, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 268 | $11.6K |
| Sep 18, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 132 | $5.7K |
| Aug 26, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 1,707 | $67.4K |
| Aug 26, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 3,465 | $136.9K |
| Aug 26, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 21,661 | $844.2K |
| Aug 26, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 43,978 | $1.71M |
| Aug 25, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 1,058 | $42.2K |
| Aug 25, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 50,270 | $1.99M |
| Aug 25, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 24,760 | $978.7K |
| Aug 25, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 2,149 | $85.8K |
| Aug 22, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 2,809 | $114.0K |
| Aug 22, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 5,668 | $230.1K |
| Aug 22, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 10,076 | $403.3K |
| Aug 22, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 20,493 | $820.3K |
| Aug 18, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 15,085 | $581.7K |
| Aug 18, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 30,628 | $1.18M |
| Aug 15, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 145,051 | $5.73M |
| Aug 15, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 69,949 | $2.76M |
| Jul 10, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 191,376 | $6.51M |
| Jun 27, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 200,000 | $6.09M |
| Jun 20, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 100,877 | $3.06M |
| Jun 20, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 133,924 | $4.05M |
| Jun 18, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 100,000 | $3.00M |
| Jun 10, 2025 | Versant Venture Capital VI, L.P. 10% owner | Sale | 350,000 | $10.15M |
| Apr 9, 2025 | Olsson Shawn Chief Commercial Officer | Option exercise | 1,400 | $2.9K |
| Mar 7, 2025 | Schimmelpennink Evert B. President, CEO and Secretary | Option exercise | 4,200 | $4.4K |
| Dec 16, 2024 | Olsson Shawn Chief Commercial Officer | Option exercise | 3,333 | $6.9K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for LENZ Therapeutics, Inc.
Free account. Everything above stays public.
Write why you follow LENZ Therapeutics, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading